{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:43Z","timestamp":1772119363929,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00432-021-03668-6","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T16:03:22Z","timestamp":1622649802000},"page":"191-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Propensity-score matched analysis of the efficacy of maintenance\/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-0752","authenticated-orcid":false,"given":"Shuji","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Koiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"3668_CR1","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782\u20131791","journal-title":"N Engl J Med"},{"key":"3668_CR2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M et al (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906\u2013917","journal-title":"N Engl J Med"},{"key":"3668_CR3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/leu.2017.256","volume":"32","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A et al (2018) Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia 32:712\u2013718","journal-title":"Leukemia"},{"key":"3668_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331","journal-title":"N Engl J Med"},{"key":"3668_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC et al (2019) Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393:253\u2013264","journal-title":"Lancet"},{"key":"3668_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad\u00e9 J et al (2020a) Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J 10:17","journal-title":"Blood Cancer J"},{"key":"3668_CR7","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.20.02060","volume":"38","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, \u0160pi\u010dka I, Quach H, Oriol A, H\u00e1jek R, Garg M et al (2020b) Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial. J Clin Oncol 38:4030\u20134041","journal-title":"J Clin Oncol"},{"key":"3668_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"3668_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519\u2013527","journal-title":"Lancet"},{"key":"3668_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV et al (2020) Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 10:53","journal-title":"Blood Cancer J"},{"key":"3668_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M et al (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301\u2013310","journal-title":"Blood"},{"key":"3668_CR12","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N et al (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104\u20132115","journal-title":"N Engl J Med"},{"key":"3668_CR13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosinol L, Holstein SA, Moreau P, Spada S et al (2018) Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol 4:1389\u20131397","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"3668_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-136907","volume":"136","author":"F Gay","year":"2020","unstructured":"Gay F, Musto P, Rota Scalabrini D, Galli M, Belotti A, Zamagni E et al (2020) Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized Forte trial. Blood 136(suppl 1):35\u201337","journal-title":"Blood"},{"key":"3668_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S et al (2018) Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia 32:383\u2013390","journal-title":"Leukemia"},{"key":"3668_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","volume":"34","author":"H Goldschmidt","year":"2020","unstructured":"Goldschmidt H, Mai EK, D\u00fcrig J, Scheid C, Weisel KC, Kunz C et al (2020) Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 34:1853\u20131865","journal-title":"Leukemia"},{"key":"3668_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41409-018-0177-6","volume":"53","author":"J Huang","year":"2018","unstructured":"Huang J, Phillips S, Byrne M, Chinratanalab W, Engelhardt BG, Goodman SA et al (2018) Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant 53:701\u2013707","journal-title":"Bone Marrow Transplant"},{"key":"3668_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"3668_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C et al (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57\u201373","journal-title":"Lancet Oncol"},{"key":"3668_CR20","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","volume":"2","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, Abonour R, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ et al (2018) Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv 2:1608\u20131615","journal-title":"Blood Adv"},{"key":"3668_CR21","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT et al (2020) Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 38:1928\u20131937","journal-title":"J Clin Oncol"},{"key":"3668_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"3668_CR23","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"3668_CR24","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128","journal-title":"Leukemia"},{"key":"3668_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S et al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378:518\u2013528","journal-title":"N Engl J Med"},{"key":"3668_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A et al (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132\u2013141","journal-title":"Lancet"},{"key":"3668_CR27","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770\u20131781","journal-title":"N Engl J Med"},{"key":"3668_CR28","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35:3279\u20133289","journal-title":"J Clin Oncol"},{"key":"3668_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/bmt.2015.83","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Richardson PG, McCarthy PL, Attal M (2015) Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplant 50:1024\u20132019","journal-title":"Bone Marrow Transplant"},{"key":"3668_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394:29\u201338","journal-title":"Lancet"},{"key":"3668_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","volume":"119","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM et al (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7\u201315","journal-title":"Blood"},{"key":"3668_CR32","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M et al (2020) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 4:5988\u20135999","journal-title":"Blood Adv"},{"key":"3668_CR33","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H et al (2015) Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5:e349","journal-title":"Blood Cancer J"},{"key":"3668_CR34","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R et al (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28:5101\u20135109","journal-title":"J Clin Oncol"},{"key":"3668_CR35","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759\u20131769","journal-title":"N Engl J Med"},{"key":"3668_CR36","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V et al (2014a) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32:634\u2013640","journal-title":"J Clin Oncol"},{"key":"3668_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al (2014b) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895\u2013905","journal-title":"N Engl J Med"},{"key":"3668_CR38","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015a) Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33:2863\u20132869","journal-title":"J Clin Oncol"},{"key":"3668_CR39","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I et al (2015b) Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol 33:3459\u20133466","journal-title":"J Clin Oncol"},{"key":"3668_CR40","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754\u2013766","journal-title":"N Engl J Med"},{"key":"3668_CR41","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML et al (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456\u20132464","journal-title":"Blood"},{"key":"3668_CR42","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95:548\u2013567","journal-title":"Am J Hematol"},{"key":"3668_CR43","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"3668_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","volume":"126","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Richardson P, San MJ (2015) Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood 126:921\u2013922","journal-title":"Blood"},{"key":"3668_CR45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbmt.2016.11.010","volume":"23","author":"D Sivaraj","year":"2017","unstructured":"Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y et al (2017) Outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant 23:262\u2013268","journal-title":"Biol Blood Marrow Transplant"},{"key":"3668_CR46","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30:2946\u20132955","journal-title":"J Clin Oncol"},{"key":"3668_CR47","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136:936\u2013945","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03668-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T23:30:30Z","timestamp":1666999830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03668-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3668"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03668-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-401187\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HH received consultation fees from Janssen and Takeda; honoraria from Janssen, Takeda, Celgene, Bristol-Myers Squibb, Ono, and Sanofi; research funding from Celgene, Janssen, and Takeda; and scholarship fund from Takeda, Kyowa Kirin, Chugai, and Daiichi-Sankyo. KS received honoraria from Celgene, Ono, Bristol-Myers Squibb, and Takeda; and research funding from Sanofi, AbbVie, Takeda, Bristol-Myers Squibb, Daiichi-Sankyo, Celgene, Alexion, Ono, Novartis, MSD, Astellas-Amgen, GSK, and Janssen. TI received honoraria from Sanofi, Takeda, Ono, Celgene, and Janssen. SI received honoraria from Sanofi, Daiichi-Sankyo, Takeda, Ono, Celgene, and Janssen; and research funding from AbbVie, Kyowa Kirin, Chugai, Sanofi, Bristol-Myers Squibb, Daiichi-Sankyo, Takeda, Ono, Celgene, and Janssen. YN received honoraria from Celgene, Chugai, Janssen, and Sanofi. KS received honoraria from Takeda, Janssen, Bristol-Myers Squibb, and Celgene. NN received honoraria from Janssen, Ono, Sanofi, and Bristol-Myers Squibb.\u00a0HM received consultation fees from Sanofi; research funding from Bristol-Myers Squibb; and scholarship fund from Daiichi-Sankyo and Takeda. All other authors have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and the institutional guidelines. Study protocol and amendments were reviewed by the Ethics Committee\/Institutional Review Board of Gunma University and institutional review boards at each center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}